THYROID CANCERS

A recent white paper determines that the link between GLP-1 agonist inhibitors and thyroid cancer is unconvincing.

During a live event, Lori Wirth, MD, discussed preferred treatment for thyroid cancer with and without a RET, NTRK, or ALK fusion.

During a live event, Lori Wirth, MD, discussed next steps for treating a patient with progressive, radioactive iodine–refractory differentiated thyroid cancer.

A groundbreaking study reveals the effectiveness of dabrafenib and trametinib in treating advanced thyroid cancer, showcasing significant survival benefits.

Innovative NBTXR3 shows promise in enhancing radiotherapy for recurrent head and neck cancer, potentially transforming treatment options for patients.

Long-term study reveals active surveillance is a safe management strategy for low-risk papillary thyroid cancer, especially in older patients.

FDA lifts REMS program for vandetanib, affirming safety in thyroid cancer treatment as healthcare providers ensure effective heart rhythm monitoring.

Larotrectinib shows promising efficacy and safety as a first-line treatment for TRK fusion cancer in both adults and children.

New study reveals plixorafenib shows significant clinical benefits for thyroid cancer patients with BRAF mutations, offering hope for targeted therapies.

The FDA fast-tracks CRB-701, an innovative ADC for advanced head and neck cancer, showing promising efficacy and safety in ongoing trials.

A phase 2 study reveals autologous TIL therapy's potential to stabilize recurrent head and neck cancer, offering hope for improved treatment options.

BioAtla's ozuriftamab vedotin advances to phase 3 trials for HPV-positive oropharyngeal cancer, aiming for accelerated FDA approval amid rising incidence.

Final data from the VERSATILE-002 trial for HPV16-positive HNSCC shows a median overall survival of 39.3 months with PDS0101 plus pembrolizumab.

New research reveals that many patients with low-risk thyroid cancer can safely skip postoperative radioiodine ablation, reducing treatment burden and side effects.

Eftilagimod alfa shows promise as a novel immunotherapy for head and neck cancer patients with low PD-L1 expression, offering new treatment hope.

CUE-101 combined with pembrolizumab shows promising results, achieving a 50% response rate in HPV-positive head and neck cancer patients.

Zenith Epigenetics' ZEN-3694 gains FDA fast track designation, offering hope for patients with aggressive NUT carcinoma through innovative treatment combinations.

New research suggests that certain patients with low-risk thyroid cancer can safely forgo postoperative radioiodine ablation without compromising long-term outcomes.

Perioperative pembrolizumab enhances survival rates in advanced head and neck cancer, paving the way for earlier immunotherapy integration and future treatment strategies.

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

A groundbreaking trial explores pembrolizumab's role in enhancing treatment outcomes for advanced head and neck cancer, promising significant advancements in patient care.

An updated analysis on larotrectinib showed compelling data in TRK fusion thyroid carcinoma.

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head and neck cancer per KEYNOTE-689, introducing a potential new standard of care.

A small papillary thyroid cancer study demonstrates favorable outcomes and highlights the role of American Thyroid Association risk stratification.